A Phase I Study of GBR 1342 Immunotherapy in Patients with Recurrent or Persistent Multiple Myeloma

Full Title

GBR 1342-101: A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Purpose

The purpose of this study is to find the highest dose of the investigational immunotherapy drug GBR 1342 that can be given safely in patients with multiple myeloma that has come back or continued to grow despite prior therapy. GBR 1342 was developed to activate specific cells of the immune system to target multiple myeloma cells. It recognizes tumor cells as well as normal white blood cells called lymphocytes. GBR 1342 causes the lymphocytes to which it attaches to attack and kill multiple myeloma cells. It is given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have multiple myeloma that has come back or continued to grow despite prior therapy.
  • Patients should recover from the serious side effects of previous treatments before entering the study.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information and to inquire about eligibility for this study, please contact Dr. Ola Landgren at 212-639-5126.

Protocol

18-046

Phase

I

Investigator

Co-Investigators